TSX:GUDPharmaceuticals
Knight Therapeutics Q4 Profit Tests Bullish Earnings Narrative After Yearlong Loss
Knight Therapeutics FY 2025 earnings snapshot
Knight Therapeutics (TSX:GUD) has wrapped up FY 2025 with Q4 revenue of C$133.1 million and basic EPS of C$0.09, capping a year where the trailing twelve month figures show C$450.1 million in revenue and a basic EPS loss of C$0.05. Over recent quarters, revenue has moved from C$96.9 million in Q4 2024 to C$88.1 million in Q1 2025, C$107.4 million in Q2 2025, C$121.5 million in Q3 2025 and C$133.1 million in Q4 2025. Quarterly EPS has ranged...